🏥 Health
2d ago
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
Source ↗
👁 0
💬 0
(MedPage Today) -- The FDA on Friday approved belzutifan (Welireg) plus pembrolizumab (Keytruda, Keytruda Qlex) as adjuvant therapy for renal cell carcinoma (RCC) with a clear cell component.
Based on results from LITESPARK-022, the combination...
Based on results from LITESPARK-022, the combination...
Comments (0)